Please login to the form below

Not currently logged in
Email:
Password:

Ironwood

This page shows the latest Ironwood news and features for those working in and with pharma, biotech and healthcare.

China approves Ironwood Pharma’s IBS treatment

China approves Ironwood Pharma’s IBS treatment

The product has been jointly developed by AstraZeneca. and Ironwood, and is expected to be launched in China in the second half of 2019, with. ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion. Ironwood and Allergan (its US marketing partner)

Latest news

More from news
Approximately 5 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    In a "mirror deal" in April this year, AstraZenenca licensed US rights to Zurampic and the fixed dose combination to Ironwood Pharmaceuticals for $100m upfront and up to $165m in further

  • Deal Watch April 2016 Deal Watch April 2016

    Ironwood is paying $100m upfront for the US market plus $165m of milestones and “tiered single digit royalties”. ... 450. AstraZeneca (UK). Ironwood (US). US license and commercialisation. Lesinurad (approved) combo in development for treatment of

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.

  • Pharma deals during October 2012 Pharma deals during October 2012

    In addition, Ironwood could receive a further $125m in milestones if certain sales targets for linaclotide are met. . ... 153. Ironwood / AstraZeneca. Co-develop &co-commercialise (profit/ loss share). Linaclotide, IBS with constipation (FDA approved).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel.

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Graney most recently spent three years at Ironwood

  • Ironwood Pharmaceuticals appoints chief development officer Ironwood Pharmaceuticals appoints chief development officer

    Dr Christopher Wright joins from Axcella Health. Ironwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development officer in a role that ... will see him lead Ironwood’s regulatory

  • Proteostasis Therapeutics strengthens leadership team Proteostasis Therapeutics strengthens leadership team

    James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Ironwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors. ... Peter Hecht, CEO of Ironwood, commented on the appointment of Owens: “He has deeply probed the strategy, growth, successes and challenges of nearly every

More from appointments
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics